SpringWorks Therapeutics Inc.

11/29/2021 | Press release | Distributed by Public on 11/29/2021 05:32

SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas